Kiromic BioPharma, Inc. ( KRBP) Stock. Should you Buy or Sell? $ 0.35
-0.04 (-14.58 %)
Kiromic BioPharma, Inc. Analysis
Updated on 10-09-2022| Symbol | KRBP |
| Price | $0.35 |
| Beta | 0.000 |
| Volume Avg. | $696.05 thousand |
| Market Cap | $5.56 M |
| 52 Week Range | $0.23 - $3.706 |
Kiromic BioPharma, Inc. opened the day at $0.35 which is -14.58 % on yesterday's close. Kiromic BioPharma, Inc. has a 52 week high of $3.706 and 52 week low of $0.23, which is a difference of $3.476. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $5.56 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Kiromic BioPharma, Inc. for $5.56 M, it would take 15 years to get your money back. Kiromic BioPharma, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Kiromic BioPharma, Inc. Stock Forecast - Is Kiromic BioPharma, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Strong Sell | |
| DE Score | Buy | |
| PE Score | Neutral | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.170 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Kiromic BioPharma, Inc.
| Price Book Value Ratio | 0.469 | Price To Book Ratio | 0.469 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.170 |
How liquid is Kiromic BioPharma, Inc.
| Current Ratio | 1.346 |
| Quick Ratio | 1.091 |
Debt
| Debt Ratio | 0.396 | Debt Equity Ratio | 0.657 |
| Long Term Debt To Capitalization | 0.131 | Total Debt To Capitalization | 0.164 |
Latest news about Kiromic BioPharma, Inc.
Kiromic BioPharma Inc (NASDAQ: KRBP) has completed the construction of its expanded current good manufacturing practice manufacturing facility in Houston. The expanded facility located at Kiromic's headquarters is one of the conditions required for the Company to begin.
Top penny stocks to watch this week. The post Top Penny Stocks To Buy Today?
Kiromic BioPharma Inc (NASDAQ: KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT. Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022.
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.
Kiromic BioPharma (KRBP) stock is rocketing higher on Tuesday following announcing a new sponsored research agreement (SRA). The post Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today?
About Kiromic BioPharma, Inc.
Description :
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
